Distribution of 1-(2-Deoxy-2-fluoro-β-d-arabinofuranosyl) Uracil in Mice Bearing Colorectal Cancer Xenografts
暂无分享,去创建一个
Paul Kinahan | C. Mathis | M. Egorin | J. Collins | J. Eiseman | E. Joseph | S. Pan | R. Klecker | L. Anderson | C. Brown-Proctor | Deborah R. Hamburger
[1] Roger N Gunn,et al. 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. , 2003, Journal of the National Cancer Institute.
[2] A. Shields,et al. Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. , 2003, Nuclear medicine and biology.
[3] W. Ichikawa,et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] Norman Wolmark,et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] T. Kovács,et al. Prognostic Significance of the Thymidylate Biosynthetic Enzymes in Human Colorectal Tumors , 2002, Oncology.
[6] S. Monfardini,et al. Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. , 2002, Cancer treatment reviews.
[7] D W. Townsend,et al. Combined PET/CT Imaging in Oncology. Impact on Patient Management. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[8] Thomas E. Nichols,et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] J. Collins,et al. Suicide prodrugs activated by thymidylate synthase: rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] G. Peters,et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] J. Collins,et al. Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells. , 1994, Molecular pharmacology.
[12] K. Bélanger,et al. Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver , 1988, Clinical pharmacology and therapeutics.
[13] K. Hamacher,et al. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] C. Pochedly. Cancer: Principles and Practice of Oncology, 2nd ed , 1986 .
[15] A. Calvert,et al. Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. , 1984, Biochemical pharmacology.
[16] R. Diasio,et al. Improved measurement of thymidylate synthetase activity by a modified tritium-release assay. , 1982, Journal of biochemical and biophysical methods.
[17] O. Muzik,et al. Imaging [18F]FAU [1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) uracil] in dogs. , 2003, Nuclear medicine and biology.
[18] Hui Wang,et al. Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. , 2002, Cancer chemotherapy and pharmacology.